Financial Data and Key Metrics Changes - For Q4 2025, reported sales increased by 14% to $963 million, up from $848 million in the prior year, while core sales grew by 5% [3][4] - Full-year reported sales rose by 5% to $3.8 billion, compared to $3.6 billion in the previous year, with core sales up by 2% [6][25] - Reported net income increased by 5% to $393 million, and reported earnings per share grew by 7% to $5.89 [6][25] - Adjusted earnings per share were $5.74, a slight decline of 1% compared to the prior year [7][25] - Adjusted EBITDA margin decreased to 19.8% from 23% in the prior year due to higher production costs and unfavorable product mix [17][24] Business Line Data and Key Metrics Changes - Pharma segment core sales increased by 4%, with prescription core sales up by 1% and injectables core sales rising by 24% [17][18] - Beauty segment core sales grew by 10%, driven by strong demand in fragrance and personal care [20][21] - Closures segment core sales increased by 1%, with beverage core sales up by 7% while food core sales decreased by 1% [22] Market Data and Key Metrics Changes - Strong demand was noted in the pharma market, particularly for systemic nasal drug delivery and injectables [4][18] - The beauty market showed double-digit growth, especially in fragrance and skincare categories, indicating a recovery in consumer demand [20][21] - The closures market experienced mixed results, with beverage sales increasing while food sales declined [22] Company Strategy and Development Direction - The company is focusing on cost reduction initiatives and productivity measures to enhance operational efficiency [4][30] - Continued investment in innovation and technology is emphasized, particularly in the pharma segment with a strong pipeline of drug delivery systems [8][9] - The company aims to maintain a disciplined approach to capital allocation while returning capital to shareholders [7][26] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued strong growth in the pharma segment, excluding emergency medicine, which is expected to face headwinds [28][32] - The beauty segment is showing signs of recovery, particularly in prestige fragrance, while closures are expected to perform steadily [32] - Management remains confident in achieving long-term growth targets despite short-term challenges [28][32] Other Important Information - The company returned $486 million to shareholders in 2025 through share repurchases and dividends, marking its 32nd consecutive year of increasing dividends [7][26] - A new share repurchase authorization of up to $600 million was announced, replacing all existing authorizations [26] Q&A Session Summary Question: Is there any deceleration in GLP-1 demand in elastomers in 2026? - Management expects injectables to grow in the high single digits to low double digits, with GLP-1 being an important but not sole driver of growth [35][39] Question: What is the expectation for EBITDA margin trends throughout the year? - Margins are expected to improve significantly in the second half of the year, driven by productivity measures and reduced impact from emergency medicine declines [40][41] Question: Can you provide specifics on margin performance in beauty and closures? - Management acknowledged operational issues in beauty and closures but expects steady improvements in margins as these issues are resolved [50][51] Question: What is the outlook for emergency medicine sales? - A revenue headwind of approximately $65 million is anticipated for 2026, primarily affecting the first half of the year [28][66] Question: How does the company view growth in the Narcan business? - Management anticipates low to mid-single-digit growth from the new baseline for Narcan, with potential for geographic expansion [74] Question: What are the expectations for cough and cold product demand? - Management expects to provide updates on the strength of the cough and cold season by Q1 or Q2, with indications of a strong season this year [76]

Financial Data and Key Metrics Changes - For Q4 2025, reported sales increased by 14% to $963 million, up from $848 million in the prior year, while core sales grew by 5% [3][4] - Full-year reported sales rose by 5% to $3.8 billion, compared to $3.6 billion in the previous year, with core sales up by 2% [6][25] - Reported net income increased by 5% to $393 million, and reported earnings per share grew by 7% to $5.89, up from $5.53 a year ago [6][25] - Adjusted earnings per share were $5.74, a slight decline of 1% compared to the prior year [7][25] - Adjusted EBITDA margin for Q4 was approximately 19.8%, down from 23% in the prior year [17][24] Business Line Data and Key Metrics Changes - Pharma segment core sales increased by 4%, with prescription core sales up by 1% and consumer healthcare core sales up by 3% [17][18] - Injectables core sales surged by 24%, driven by strong demand for elastomeric components [18] - Beauty segment core sales increased by 10%, with personal care core sales rising by 17% [20][21] - Closures segment core sales increased by 1%, with beverage core sales up by 7% [22] Market Data and Key Metrics Changes - Strong demand was noted in the pharma segment, particularly for systemic nasal drug delivery technologies and injectables [4][8] - The beauty segment experienced double-digit growth across fragrance and facial skincare markets [4][20] - The closures segment saw solid product volume growth, particularly in beverages [5][22] Company Strategy and Development Direction - The company is focusing on cost reduction initiatives and back-office centralization through global talent centers [4][30] - There is an emphasis on productivity measures to mitigate higher production costs and improve margins [3][30] - The company aims to maintain a disciplined approach to capital allocation while investing in long-term growth opportunities [7][26] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued strong growth in the pharma segment, excluding emergency medicine, which is facing destocking challenges [32] - The company expects steady improvements in beauty margins and a return to growth in the closures segment [30][32] - The outlook for Q1 2026 includes adjusted earnings per share expected to be in the range of $1.13-$1.21 [29] Other Important Information - The company returned $486 million to shareholders through share repurchases and dividends in 2025 [7][26] - The company achieved a record quarter for tooling sales in Q4 2025, indicating strong customer retention [23] Q&A Session Summary Question: Is there any deceleration in GLP-1 demand in elastomers in 2026? - Management expects injectables to grow in the high single digits to low double digits, with GLP-1 being an important but not sole driver of growth [38][39] Question: What is the expectation for EBITDA margin trends throughout the year? - Management anticipates stronger margins in the second half of the year, driven by improvements in beauty and closures segments [40][41] Question: Can you provide specifics on the margin performance in beauty and closures? - Management noted operational issues in beauty due to environmental upgrades and maintenance in closures, with expectations for improvements in Q1 [50][51] Question: What is the outlook for emergency medicine sales? - Management expects a revenue headwind of approximately $65 million in 2026, primarily in the first half [28][66] Question: How should growth in Narcan and cough and cold products be expected to stabilize? - Management anticipates low to mid-single-digit growth for Narcan and expects to update on cough and cold product performance by Q2 [74][76]

Financial Data and Key Metrics Changes - For Q4 2025, reported sales increased by 14% to $963 million, up from $848 million in the prior year, while core sales grew by 5% [3][4] - Full-year reported sales rose by 5% to $3.8 billion, compared to $3.6 billion in the previous year, with core sales up by 2% [5][24] - Reported net income increased by 5% to $393 million, and reported earnings per share grew by 7% to $5.89, up from $5.53 a year ago [5][24] - Adjusted earnings per share were $5.74, a slight decline of 1% compared to the prior year [6][24] - Adjusted EBITDA margin for Q4 was approximately 19.8%, down from 23% in the prior year [17][24] Business Line Data and Key Metrics Changes - Pharma segment core sales increased by 4%, with prescription core sales up by 1% and consumer healthcare core sales up by 3% [17][18] - Injectables core sales surged by 24%, driven by strong demand for elastomeric components [18] - Beauty segment core sales increased by 10%, with personal care core sales rising by 17% [19][20] - Closures segment core sales increased by 1%, with beverage core sales up by 7% [21] Market Data and Key Metrics Changes - Strong demand was noted in the pharma segment, particularly for systemic nasal drug delivery and injectables [4][8] - The beauty segment experienced double-digit growth across fragrance and facial skincare markets [4][19] - The closures segment saw volume growth, although impacted by lower resin pricing [21] Company Strategy and Development Direction - The company is focusing on cost reduction initiatives and back-office centralization through global talent centers [4][29] - There is an emphasis on productivity measures and efficiency improvements, with expectations for continued growth in the pharma segment excluding emergency medicine [30][28] - The company aims to maintain a disciplined approach to capital allocation while investing in long-term growth opportunities [6][25] Management's Comments on Operating Environment and Future Outlook - Management anticipates near-term headwinds in emergency medicine extending through 2026, with a revenue headwind of approximately $65 million expected [26] - The company expects steady improvements in beauty margins and overall performance in the second half of 2026 [34][39] - There is confidence in the growth potential of the pharma segment, particularly in injectables and systemic nasal drug delivery technologies [30][45] Other Important Information - The company returned $486 million to shareholders in 2025 through share repurchases and dividends, marking its 32nd consecutive year of increasing dividends [6][25] - The company issued $600 million of senior notes in Q4 2025 to support its capital structure [23] Q&A Session Summary Question: Is there any deceleration in GLP-1 demand in elastomers in 2026? - Management expects injectables to grow in the high single digits to low double digits, with GLP-1 being an important but not sole driver of growth [32][33] Question: What is the expectation for EBITDA margin trends throughout the year? - Margins are expected to improve significantly in the second half of the year, driven by increased volume and productivity measures [34] Question: Can you elaborate on the margin performance in beauty and closures? - Operational issues and environmental upgrades impacted margins, but improvements are expected as these issues are resolved [39][40] Question: What is the outlook for emergency medicine sales? - Emergency medicine is expected to face challenges, with a significant decline anticipated in the first half of 2026 [26][41] Question: How does the company view the growth potential for Narcan and cough and cold products? - Management sees low to mid-single-digit growth for Narcan and anticipates a strong cough and cold season, with updates expected in Q1 and Q2 [46][48]

Core Insights - The South Korean cosmetic surgery industry is experiencing rapid growth, particularly in non-invasive procedures such as injectables and laser treatments, which are becoming increasingly popular among consumers [4][13][14] - New injectables like "Rejuran," which uses salmon DNA to enhance skin elasticity, are gaining traction, showcasing the innovative nature of the industry [5][14] - The competitive landscape in South Korea allows for a wide variety of injectables and treatments, often at lower costs compared to other countries, leading to a surge in demand [13][14] Industry Trends - The use of injectables in South Korea has become a mainstream practice, with many clinics offering a plethora of options, including "pink injections" and various types of botulinum toxin [14][19] - There is a notable difference in the regulatory environment between South Korea and the United States, with South Korea allowing more experimental procedures and a broader range of products available to consumers [13][14] - The trend towards non-invasive procedures reflects a shift in consumer preferences, as many seek less painful and lower-risk alternatives to traditional surgeries [13][15] Consumer Behavior - Consumers in South Korea are increasingly viewing cosmetic procedures as a routine part of self-care, leading to a normalization of injectables and other treatments [16][19] - The pressure to conform to beauty standards is significant, with individuals often feeling compelled to undergo procedures to meet societal expectations [16][19] - Despite the risks associated with cosmetic procedures, many consumers accept these as part of the experience, indicating a complex relationship with beauty and self-image [14][19] Medical Practices - The prevalence of cosmetic procedures has raised concerns about safety and the potential for medical errors, with reports of increasing complaints related to cosmetic surgeries [14][15] - Surgeons in South Korea often perform multiple procedures in a day, which may increase the likelihood of mistakes, highlighting the need for careful consideration of patient safety [14][15] - Some medical professionals advocate for a more cautious approach, encouraging patients to reconsider unnecessary procedures and emphasizing the importance of informed decision-making [19][20]